Table 2.
Baseline characteristics of the cohort (n = 197).
| Parameter | Value |
|---|---|
| Clinical data | |
| Age, years | 64.5 ± 10.0 |
| Female sex | 57.4% (n = 113) |
| Comorbidities potentially related to ACS | 85.9% (n = 152) |
| Diabetes | 22.3% (n = 44) |
| Hypertension | 57.9% (n = 114) |
| Dyslipidaemia | 49.0% (n = 96) |
| Obesity | 31.0% (n = 61) |
| Cerebrovascular disease | 1.0% (n = 2) |
| Cardiovascular disease | 10.7% (n = 21) |
| Body mass index (kg/m2) (n = 133) | 30.3 ± 6.3 |
| Systolic blood pressure (mmHg) (n = 159) | 137.7 ± 16.9 |
| Diastolic blood pressure (mmHg) (n = 159) | 79.7 ± 9.6 |
| Analytical data | |
| Fasting plasma glucose, nmol/L (mg/dL) (n = 197) | 5.87 ± 1.6 (105.7 ± 28.9) |
| HbA1c (%) (n = 55) | 6.2 ± 0.9 |
| LDL-c, nmol/L (mg/dL) (n = 143) | 30.03 ± 8.3 (115.5 ± 31.8) |
| HDL-c, nmol/L (mg/dL) (n = 143) | 13.96 ± 4.6 (53.7 ± 17.7) |
| Triglycerides, nmol/L (mg/dL) (n = 193) | 1.17 ± 0.6 (110.2 ± 51.1) |
| DST, nmol/L(µg/dL) (n = 197) | 66.2 ± 74.5 (2.4 ± 2.7) |
| Urinary free cortisol, nmol/24 h (µg/24 h) (n = 197) | 1092.41 ± 791.1 (39.6 ± 28.7) |
| ACTH, pmol/L (pg/mL) (n = 197) | 3.59 ± 2.6 (16.3 ± 11.6) |
| DHEAS (ng/mL) (n = 197) | 596.2 [IQR = 150–2840] |
| Late-night salivary cortisol, nmol/L(µg/dL) (n = 197) | 110.3 ± 118.6 (4.0 ± 4.3) |
| Radiological data | |
| Tumor size (mm) (n = 197) | 22.2 ± 10.5 |
| Bilaterality (n = 197) | 30.0% (n = 59) |
| Tumor rich in lipidic content (n = 155) | 85.2% (n = 132) |
ACTH adrenocorticotropic hormone, ACS autonomous cortisol secretion, DST dexamethasone suppresion test, DHEAS dehydroepiandrosterone sulphate, LDL-c low-density lipoprotein cholesterol, HDL-c high-density lipoprotein cholesterol, HbA1c hemoglobin A1c.